Developer docs
API playgroundTry for free, no card

Search company profiles

Constellation Pharmaceuticals

Full company profile

uuid0004odk

Namestring
Constellation Pharmaceuticals
Company typeenum
Private
Founded yearint
2008
Descriptiontext

Constellation Pharmaceuticals is a clinical-stage oncology biopharmaceutical company founded in 2008 and headquartered in Cambridge, Massachusetts. The company develops small-molecule drugs in the field of epigenetics, focusing on selective regulators of epigenetic function, which represent a mechanistically novel class of targeted cancer therapies. Its scientific platform was built by founding scientists David Allis, Danny Reinberg, and Yang Shi, three of the most recognized researchers in chromatin biology and epigenetic regulation, lending the company deep scientific credibility in its core therapeutic area.

The company's pipeline is centered on selective modulators of epigenetic targets, with development activity spanning hematologic malignancies and solid tumors. Business activity is funded by repeated equity financings — over $750 million raised across more than thirteen rounds between 2008 and 2019 — with consistent backing from founder-affiliated investors The Column Group, Third Rock Ventures, and Venrock, plus later-stage participation from Fidelity, Hillhouse, Deerfield, Cormorant, Casdin, OrbiMed, and Bain Capital Life Sciences. A 2012 strategic collaboration with Genentech provided both capital and validation, and the company maintains a public listing on NASDAQ under ticker CNST.

Revenue mechanics are characteristic of a pre-commercial biotech: there are no marketed products disclosed in the available sources, and any inflows would be limited to collaboration milestones rather than product sales. The organization has 101-250 employees, consistent with a mid-cap clinical development company building out commercial capabilities in advance of potential product launches.

Short descriptiontext

Constellation Pharmaceuticals is a clinical-stage oncology biopharmaceutical company developing small-molecule drugs targeting selective regulators of epigenetic function for cancer treatment, based in Cambridge, MA and listed on NASDAQ as CNST.

Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
epigenetic drug discovery, oncology therapeutics, selective regulators, cancer drug development, small molecule pharmaceuticals
Industry1 code
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Epigenetic Oncology Pharmaceuticals
Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Constellation Pharmaceuticals develops pharmaceutical drugs in the field of epigenetics, focusing on selective regulators of epigenetic function for cancer indications. The company discovers and advances small-molecule therapeutic candidates targeting chromatin and gene-expression regulatory mechanisms implicated in oncology.

Differentiator
Functional benefit
Problem solved
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage oncology company developing EZH2 and menin-MLL inhibitors. Shares Constellation's focus on selective regulators of epigenetic function in oncology, including HDAC and related chromatin-modifying targets.

TypeBroad incumbent
Description

Strategic investor in Constellation (led the 2012 $95M round) and a major oncology pharma with internal epigenetic research programs. Comparable as a partner, competitor, and potential acquirer.

TypeDirect peer
Description

Directly comparable epigenetic-focused oncology company with the FDA-approved EZH2 inhibitor Tazverik. Competes with Constellation in the same epigenetic target space and patient populations, particularly in hematologic malignancies and solid tumors.

4Forma Therapeutics
TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing small molecules targeting rare hematologic diseases and cancers, including epigenetic targets such as IDH1/2. Directly comparable in scale and pipeline focus.

TypeDirect peer
Description

Clinical-stage epigenetics company developing LSD1 and other chromatin-modifying inhibitors for oncology and CNS indications. Comparable as a focused epigenetic-mechanism drug developer.

6Bristol-Myers Squibb
TypeBroad incumbent
Description

Global oncology pharma with multiple BET and epigenetic programs in development and the commercial scale to compete or acquire in this space. Represents the dominant large-pharma competitive threat in epigenetic oncology.

TypeBroad incumbent
Description

Diversified biopharma with oncology programs including epigenetic targets. Comparable as a large-pharma acquirer and competitor in the selective chromatin regulator space.

TypeEmerging player
Description

Clinical-stage biotech developing a new class of medicines targeting the chromatin regulatory system. Highly comparable mechanistically to Constellation's focus on selective regulators of epigenetic function.

TypeEmerging player
Description

Clinical-stage precision oncology company developing a pipeline that includes PRMT5 and other chromatin-targeting agents. Comparable as an emerging epigenetic-focused oncology developer.

10Constellation Pharmaceuticals (acquired by MorphoSys context — using Celgene as comparable)
TypeBroad incumbent
Description

Large oncology specialty pharma with deep interest in epigenetic mechanisms. Broad portfolio across hematology and solid tumors with the resources and commercial reach to absorb pipeline assets of Constellation's size.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds14 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors22 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Constellation Pharmaceuticals

Epigenetic Oncology Pharmaceuticalsconstellationpharma.com

Constellation Pharmaceuticals is a clinical-stage oncology biopharmaceutical company developing small-molecule drugs targeting selective regulators of epigenetic function for cancer treatment, based in Cambridge, MA and listed on NASDAQ as CNST.

What Constellation Pharmaceuticals does

Constellation Pharmaceuticals is a clinical-stage oncology biopharmaceutical company founded in 2008 and headquartered in Cambridge, Massachusetts. The company develops small-molecule drugs in the field of epigenetics, focusing on selective regulators of epigenetic function, which represent a mechanistically novel class of targeted cancer therapies. Its scientific platform was built by founding scientists David Allis, Danny Reinberg, and Yang Shi, three of the most recognized researchers in chromatin biology and epigenetic regulation, lending the company deep scientific credibility in its core therapeutic area.

The company's pipeline is centered on selective modulators of epigenetic targets, with development activity spanning hematologic malignancies and solid tumors. Business activity is funded by repeated equity financings — over $750 million raised across more than thirteen rounds between 2008 and 2019 — with consistent backing from founder-affiliated investors The Column Group, Third Rock Ventures, and Venrock, plus later-stage participation from Fidelity, Hillhouse, Deerfield, Cormorant, Casdin, OrbiMed, and Bain Capital Life Sciences. A 2012 strategic collaboration with Genentech provided both capital and validation, and the company maintains a public listing on NASDAQ under ticker CNST.

Revenue mechanics are characteristic of a pre-commercial biotech: there are no marketed products disclosed in the available sources, and any inflows would be limited to collaboration milestones rather than product sales. The organization has 101-250 employees, consistent with a mid-cap clinical development company building out commercial capabilities in advance of potential product launches.

Constellation Pharmaceuticals firmographics

Firmographics
Name
Constellation Pharmaceuticals
Website
https://constellationpharma.com
Company type
Private
Founded year
2008
Headcount range
101–250 employees
Short description
Constellation Pharmaceuticals is a clinical-stage oncology biopharmaceutical company developing small-molecule drugs targeting selective regulators of epigenetic function for cancer treatment, based in Cambridge, MA and listed on NASDAQ as CNST.
Ownership category
akta.pro rank

Constellation Pharmaceuticals industry classification

Industry
Product category
Epigenetic Oncology Pharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals

Keywords

  • Epigenetic drug discovery
  • Oncology therapeutics
  • Selective regulators
  • Cancer drug development
  • Small molecule pharmaceuticals

Where Constellation Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Markets served

Constellation Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Constellation Pharmaceuticals product offering

Product offering

Core offering

Constellation Pharmaceuticals develops pharmaceutical drugs in the field of epigenetics, focusing on selective regulators of epigenetic function for cancer indications. The company discovers and advances small-molecule therapeutic candidates targeting chromatin and gene-expression regulatory mechanisms implicated in oncology.

Differentiator

Problem solved

Functional benefit

Companies that use Constellation Pharmaceuticals

Customer profile

Ideal customer profiles1 record

Constellation Pharmaceuticals technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Constellation Pharmaceuticals partnerships and signals

Strategic signal

Recent moves6 records

Expansion highlights4 records

Constellation Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Syndax Pharmaceuticals: Clinical-stage oncology company developing EZH2 and menin-MLL inhibitors. Shares Constellation's focus on selective regulators of epigenetic function in oncology, including HDAC and related chromatin-modifying targets.
  • Epizyme: Directly comparable epigenetic-focused oncology company with the FDA-approved EZH2 inhibitor Tazverik. Competes with Constellation in the same epigenetic target space and patient populations, particularly in hematologic malignancies and solid tumors.
  • Forma Therapeutics: Clinical-stage biopharmaceutical company developing small molecules targeting rare hematologic diseases and cancers, including epigenetic targets such as IDH1/2. Directly comparable in scale and pipeline focus.
  • Oryzon Genomics: Clinical-stage epigenetics company developing LSD1 and other chromatin-modifying inhibitors for oncology and CNS indications. Comparable as a focused epigenetic-mechanism drug developer.

Broad incumbents

  • Roche / Genentech: Strategic investor in Constellation (led the 2012 $95M round) and a major oncology pharma with internal epigenetic research programs. Comparable as a partner, competitor, and potential acquirer.
  • Bristol-Myers Squibb: Global oncology pharma with multiple BET and epigenetic programs in development and the commercial scale to compete or acquire in this space. Represents the dominant large-pharma competitive threat in epigenetic oncology.
  • AbbVie: Diversified biopharma with oncology programs including epigenetic targets. Comparable as a large-pharma acquirer and competitor in the selective chromatin regulator space.
  • Constellation Pharmaceuticals (acquired by MorphoSys context — using Celgene as comparable): Large oncology specialty pharma with deep interest in epigenetic mechanisms. Broad portfolio across hematology and solid tumors with the resources and commercial reach to absorb pipeline assets of Constellation's size.

Emerging players

  • Foghorn Therapeutics: Clinical-stage biotech developing a new class of medicines targeting the chromatin regulatory system. Highly comparable mechanistically to Constellation's focus on selective regulators of epigenetic function.
  • Prelude Therapeutics: Clinical-stage precision oncology company developing a pipeline that includes PRMT5 and other chromatin-targeting agents. Comparable as an emerging epigenetic-focused oncology developer.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights5 records

Customer concentration

Constellation Pharmaceuticals social profiles

Digital presence

Constellation Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Constellation Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles5 records

Constellation Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds14 records

Investors22 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Constellation Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Constellation Pharmaceuticals

What does Constellation Pharmaceuticals do?

Constellation Pharmaceuticals develops pharmaceutical drugs in the field of epigenetics, focusing on selective regulators of epigenetic function for cancer indications. The company discovers and advances small-molecule therapeutic candidates targeting chromatin and gene-expression regulatory mechanisms implicated in oncology.

When was Constellation Pharmaceuticals founded?

Constellation Pharmaceuticals was founded in 2008. It employs 101 to 250 people.

Where is Constellation Pharmaceuticals based?

Constellation Pharmaceuticals is headquartered in Cambridge, United States, in the North America region.

Who are Constellation Pharmaceuticals's main competitors?

Direct peers on record are Syndax Pharmaceuticals, Epizyme, Forma Therapeutics and Oryzon Genomics. Broad incumbents are Roche / Genentech, Bristol-Myers Squibb, AbbVie and Constellation Pharmaceuticals (acquired by MorphoSys context — using Celgene as comparable). Emerging players are Foghorn Therapeutics and Prelude Therapeutics.

Does Constellation Pharmaceuticals have an API?

No public API is recorded for Constellation Pharmaceuticals.

What industry is Constellation Pharmaceuticals in?

Constellation Pharmaceuticals's product category is Epigenetic Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioWorldConstellation Pharmaceuticals discovers new TREX1 inhibitors for cancerConstellation Pharmaceuticals Inc. has described three-prime repair exonuclease 1 (TREX1) inhibitors reported to be useful for the treatment of cancer. The company's description of these inhibitors was published on November 24, 2022.BioSpaceAadi Bioscience Appoints Brendan Delaney as Chief Operating OfficerAadi Bioscience appointed Brendan Delaney as Chief Operating Officer. He previously led commercial teams at Constellation Pharmaceuticals and Immunomedics, including TRODELVY and pelabresib. He will support the November 2021 PDUFA target for ABI-009 and plan a tumor-agnostic trial by year-end.PharmiWeb.comMorphoSys to Complete Transformational Acquisition of Constellation Pharmaceuticals, Bolstering Its Position in Hematology-OncologyMorphoSys announced on July 15, 2021 the completion of its cash tender offer for all outstanding shares of Constellation Pharmaceuticals at $34.00 per share, net to sellers, with about 42.8 million shares tendered, roughly 89% of outstanding shares. The deal's total equity value is about $1.7 billion, closing via a second-step merger with Constellation surviving as an indirect wholly owned subsidiary. MorphoSys will remain in Munich, with a significant Boston presence.BioWorldIs big pharma falling back in love with small molecules?Morphosys AG acquired Constellation Pharmaceuticals in a $1.7 billion deal in June, using royalty proceeds from a big-selling antibody to fund research into small-molecule BET inhibitors. The move signals renewed interest in small-molecule drugs after antibody-based molecules dominated the branded-drug market.PR NewswireMoore Kuehn Encourages USCR, QTS, CNST and ESXB Investors to Contact Law FirmMoore Kuehn, a New York-based securities litigation law firm, announced it is investigating four proposed mergers for potential shareholder fairness concerns, examining whether the boards acted to maximize shareholder value, disclosed material information, and conducted fair processes. The four mergers under scrutiny involve U.S. Concrete/Vulcan Materials ($74.00/share), QTS Realty Trust/Blackstone ($78.00/share), Constellation Pharmaceuticals/MorphoSys AG ($34.00/share), and Community Bankers Trust/United Bankshares (0.3173 share exchange). The law firm is soliciting affected shareholders to contact them, warning that there may be limited time to enforce their rights.PR NewswireSHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Constellation Pharmaceuticals, Inc. - CNSTMonteverde & Associates PC announced an investigation into the proposed acquisition of Constellation Pharmaceuticals, Inc. by MorphoSys AG, under which CNST shareholders would receive $34.00 per share in cash. The law firm is examining whether Constellation and its Board violated securities laws or breached fiduciary duties by failing to conduct a fair process and whether the transaction is properly valued. Shareholders who owned common stock in the company can obtain additional information through the firm's website.FinSMEsMorphoSys to Buy Constellation Pharmaceuticals, for $1.7 BillionMorphoSys AG has agreed to acquire Constellation Pharmaceuticals, Inc. for a total equity value of $1.7 billion, with the transaction expected to close in the third quarter of 2021. To finance the deal and support pipeline development, MorphoSys also entered into a strategic funding partnership with Royalty Pharma plc, which includes up to $350 million in Development Funding Bonds and potential milestone payments. The acquisition will expand MorphoSys's oncology portfolio by adding Constellation's lead candidates, pelabresib and CPI-0209, which are currently in mid- to late-stage clinical trials.YahooWhy Constellation Pharmaceuticals Stock Was Crushing It This WeekConstellation Pharmaceuticals stock rose 70.6% after MorphoSys announced a $1.7 billion cash offer for the biotech. The $34-per-share deal represents a nearly 72% premium over last week's closing price.Benzinga66 Biggest Movers From Yesterday - AMC Entertainment Hldgs (NYSE:AMC)This article lists the biggest stock market movers from the previous trading day, highlighting significant gains and losses across various sectors. Key events include AMC Entertainment's 95% surge following a $230.5 million equity raise from Mudrick Capital, and MorphoSys AG agreeing to acquire Constellation Pharmaceuticals for $1.7 billion. The report also covers other notable movements such as GameStop's rise ahead of earnings and iRhythm Technologies' decline due to CEO resignation and analyst downgrade.PR NewswireSHAREHOLDER ALERT: WeissLaw LLP Investigates Constellation Pharmaceuticals, Inc.WeissLaw LLP announced an investigation into the board of directors of Constellation Pharmaceuticals for potential breaches of fiduciary duty in connection with the proposed acquisition by MorphoSys AG at $34.00 per share. The law firm is examining whether the all-cash tender offer adequately compensates Constellation shareholders, noting that multiple analysts have set price targets for Constellation above the offer price, with a high target of $75.00. WeissLaw LLP is seeking information from shareholders who wish to discuss the investigation or their rights regarding the transaction.